Bristol-Myers: I'm Buying Post Earnings

Group 1 - Bristol-Myers Squibb Company (NYSE: BMY) has been recognized as a significant winner in the pharmaceutical sector since a strong buy rating was issued in late October, attributed to its successful execution of strategies [1] - The focus is on analyzing undervalued and disliked companies or industries with strong fundamentals and good cash flows, particularly in sectors like Oil & Gas and consumer goods [1] - Energy Transfer is highlighted as a company that was previously overlooked but has shown potential, indicating a long-term value investing approach [1] Group 2 - The article emphasizes a preference for long-term value investing while acknowledging occasional interest in deal arbitrage opportunities, such as those involving Microsoft/Activision Blizzard and Spirit Airlines/Jetblue [1] - There is a clear aversion to investing in businesses that are not well understood, particularly in high-tech and certain consumer goods sectors [1] - The article expresses skepticism towards cryptocurrencies, indicating a focus on more traditional investment avenues [1]